{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:09Z","timestamp":1750538409521,"version":"3.41.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Adenoid cystic carcinoma (ACC) is a rare cancer that arises from salivary glands and other secretory glands. Pulmonary metastases are frequently observed in ACC patients with metastatic disease. Previous research showed that ACC often shows high PSMA uptake on <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT. Here, we present PET images from an ACC patient with pulmonal, pleural metastases, and malignant pleural effusion, with comparable tracer uptake on <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET and <jats:sup>18<\/jats:sup>F-FDG PET.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004015","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T16:02:15Z","timestamp":1641830535000},"page":"140-141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["68Ga\u2013Prostate-Specific Membrane Antigen\u2013Avid Malignant Pleural Effusion in a Patient With Metastatic Adenoid Cystic Carcinoma and Concordance With 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"47","author":[{"given":"Maike Jos\u00e9 Maria","family":"Uijen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Radboud Institute for Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jetty Anne Mina","family":"Weijers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud Institute for Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal Maria Leonarda","family":"Driessen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud Institute for Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Marie Louise","family":"van Herpen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud Institute for Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9610(97)00153-0","article-title":"Distant metastasis in adenoid cystic carcinoma of salivary origin","volume":"174","year":"1997","journal-title":"Am J Surg"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/archotol.129.11.1193","article-title":"Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck","volume":"129","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","year":"2011","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","year":"1996","journal-title":"Ann Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1200\/JCO.2018.36.15_suppl.6026","article-title":"Phase II trial of apatinib in patients with recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck: updated analysis","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"bib8-20250621","first-page":"6529","article-title":"A phase II study on the efficacy and toxicity of cabozantinib in recurrent\/metastatic salivary gland cancer patients","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.7150\/thno.38501","article-title":"68Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study","volume":"10","year":"2020","journal-title":"Theranostics"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/RLU.0000000000002748","article-title":"68Ga-prostate-specific membrane antigen uptake in a malignant pleural effusion from metastatic prostate cancer after pleurodesis","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:07:31Z","timestamp":1750536451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004015","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}